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Tuberculosis is the principal cause of death from infection in the world. The resurgence of tuberculosis and 
the increase in mycobacterial infections, as well as multidrug-resistance of mycobacteria to available 
antibiotics, has incentivized research on new antimycobacterial agents.  Therefore, research based on 
water and soil samples from the Moroccan biotopes, has led to the isolation of a bacterial strain capable of 
inhibiting mycobacterial growth (Mycobacterium smegmatis and Mycobacterium aurum A
+
). The effect was 
due to an active substance secreted into the culture medium. Sequencing of the 16S rRNA gene identified 
the strain as belonging to the species Staphylococcus warneri. The active substance precipitated using 
ammonium sulfate, maintained its inhibitory properties, which were lost when treated with proteinase K. 
These results indicated that the active substance was protein. Study of the activity of the metabolite 
revealed its effect on M. smegmatis cell wall, facilitating genomic DNA extraction.   
 





Tuberculosis, caused by Mycobacterium tuberculosis, 
undeniably remains a menacing social disease (Musser, 
1995; Berthet et al., 1999; Rossetti et al., 2002). Never-
theless, as of 1952, the onset of effective chemotherapy, 
followed by widespread Bacille de Calmette et Guérin 
(BCG) vaccination (Ann Ginsberg, 2002; Bonnaud, 
1996), the discovery of effective antituberculosis agents 
and the improvement of living conditions, have led to a 
considerable decline in tuberculosis in industrialized na-
tions. In fact, the rate of infection dropped from 
200/100.000 inhabitants in 1900 to less than 10/100.000 
inhabitants in 1980 (Rastogi et al., 2001; Jost et al., 
2001). 
However, in the early 90’s, population mobility, econo-
mic and political migrations, together with ineffective 
tuberculosis control programs, where adequate treatment 
failed to reach many patients,  gave rise to an increase in 
the global incidence of tuberculosis (Newton et al., 2000). 
These conditions also favored the onset of problematic 
multidrug-resistant strains (Jost et al., 2001). Further-
more, immunocompromised patients, especially those 
infected by the human immunodeficiency virus (HIV),
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are particularly vulnerable (Mohle-Boetani et al., 2002; 
Chin and Hopewell, 1996). Developing countries remain 
the most affected by tuberculosis with mortality rates 
close to 40% compared to 7% in the industrialized 
nations (Emile, 1996). 
In spite of scientific progress, this disease continues to 
take its toll mainly in the poorer regions of the globe 
(Dharmarajan et al., 2007). According to the World Health 
Organization (WHO) 2010 report, more than two billion 
people, close to one third of the world’s population, are 
contaminated with the tuberculosis bacillus. One out of 
ten infected individuals will develop active disease in the 
course of his or her lifetime. The risk is considerably 
higher for people living with HIV. WHO has estimated that 
between 2000 and 2020, close to one billion people will 
be newly infected and that 200 million of these will 
develop the disease, of these 35 million will die of 
tuberculosis, if adequate measures are not taken to 
improve disease control (WHO, 2005). 
Resistance to antituberculosis agents is due to insuf-
ficient treatment in either duration or dosage. There are 
two forms of resistance, multidrug-resistance and exten-
sive drug-resistance. In 2007, the estimate was of 500 
000 tuberculosis cases due to multidrug-resistant tuber-
culosis bacilli (MDRTB); 85% of these were from 27 
countries (of which 15 were from the European region). 
By the end of 2008, 55 countries and territories had 
reported at least one case of extensively drug-resistant 
tuberculosis (XDRTB) (WHO, 2009). In Morocco, 500 to 
1.000 people die every year from tuberculosis. According 
to the latest reports from the Ministry of Health, the 
kingdom registered 25.500 new cases in 2007, corres-
ponding to 82 cases for every 100.000 inhabitants. Seventy 
percent of these patients were between 15 and 45 years 
of age (Ben cheikh et al., 1996), and those populations 
from urban populated areas remain the most vulnerable. 
The WHO, the Global Fund to Fight AIDS, Tuberculosis 
and Malaria and the Stop TB Partnership have appealed 
to world leaders to reinforce their commitment and 
increase their contributions so as to reach the objective of 
one million people diagnosed and treated against 
MDRTB between 2011 and 2015, implicating the neces-
sity of developing new and effective antimycobacterial 
agents (Newton et al., 2000). The production of antimicrobial 
compounds is a phenomenon observed amongst an 
important number of, mainly Gram positive, bacteria 
(Sosunov et al., 2007). This corresponds to a defensive 
mechanism of these bacteria, through the production of 
antibiotics, organic acids, and lytic agents such as lyso-
zymes. Furthermore, several types of protein exotoxins, 
and bacteriocins are produced (Mota et al., 2004). The 
purpose of this investigation is to search for new antimy-
cobacterial substances from the Moroccan bacterial flora, 
that has not been extensively explored, that could 
improve control of mycobacterial infections bringing a 
solution to the problem caused by the emergence of 









The tests were performed on non-pathogenic mycobacteria. These 






A rapid growing scotochromogenic species, with a generation time 
of 6 h having a similar spectrum of drug susceptibility to M. 
tuberculosis (Chung et al., 1995). Accordingly, this strain has been 
proposed as a surrogate for antimycobacterial drug discovery 






A thermophilic, nonpigmented species (cultures may turn yellow 
with time). This is a rapidly growing species having a generation 
time of 3 h. This species has been used as a model in antituber-
culosis drug discovery (Mitscher et al., 1998). 
 
 
Isolation of a bacterial strain secreting a metabolite with 
antimycobacterial effect 
 
Several samples (water, soil and water) were taken from different 
Moroccan ecological niches. The samples were kept under agita-
tion for 2 h. The supernatant was recovered after sedimentation of 




) were carried 
out in sterile Luria Bertoni (LB) broth (peptone: 10 g/l; yeast extract: 
5 g/l; sodium chloride: 10 g/l). An aliquot of 70 µl of each dilution 
was spread on LB-agar previously inoculated with M. aurum A
+
 or 
M. smegmatis cultures having an optical density at 600 nm 
(OD600nm) of 0.3. After incubation at 37°C for 48 h, one colony 
surrounded by an inhibition zone was isolated.  
To confirm that the antimycobacterial effect of this isolate was 
due to secreted substances, their cultures were filtered and the 
filtrate was tested on the mycobacteria using the well or diffusion 
method according to the following protocol: The bacterial strain was 
cultured in 50 ml of LB broth, for 48 h at 37°C with agitation; then 
centrifuged at 6000 rpm for 5 min to remove bacteria in suspension. 
The supernatant was recovered and filtered using 0.45 μm porosity 
filters. The filtrate obtained was tested by depositing 100 µl in wells 
cut out from solid media in plates previously inoculated with 100 μl 
of mycobacterial culture (M. aurum or M. smegmatis) at OD600nm = 
0.3. The plates were incubated at 37°C for 48 h. After incubation, 
the presence or absence of an inhibition zone was reported. The 
inhibition tests were repeated three times for each strain. 
The control used was a culture filtrate from Escherichia coli 
prepared under the same conditions. 100 µl of this filtrate was 
deposited in the wells prepared in plates previously inoculated with 
mycobacterial culture (M. aurum or M. smegmatis) at OD600nm = 0.3. 
The plates were incubated at 37°C for 48 h. After incubation, the 
presence or absence of an inhibition zone was reported. 
 
 
Activity spectrum of the isolate 
 
In order to get an idea on the spectrum of activity, the antimicrobial 
effect of the isolates under study was evaluated against the 





 155, Escherichia coli DH5α, Bacillus subtilis (EL 
Guendouzi et al., 2011), Staphylococcus haemolyticus (Hassi et al., 
2007). The test was repeated three times for each strain.  A few 
colonies from young cultures of the isolate were deposited at the 





ture (for E. coli, B. subtilis and S. haemolyticus the D.O600nm was at 
0.5, for M. aurum and M. smegmatis the D.O600nm was at 0.3). The 
plates were incubated at 37°C for 48 h. The presence or absence of 
an inhibition zone was then reported. 
 
 
Identification of the isolate 
 
The identification of the isolate was based on rRNA gene 
sequencing. This is the molecular approach more commonly used 
in bacterial phylogeny (Woese et al., 1990). It has permitted the 
constitution of important databases (Maidack et al., 1996; Van de 
Peer et al., 1999), and its use has led to the identification of several 
microorganisms from the environment including when culture was 
not successful (Relman et al., 1992; Strous et al., 1999). A 1 ml 
aliquot from a young LB broth culture of the isolate (24 hours) was 
transferred to a 1.5 ml microtube. The tube was centrifuged at 6000 
rpm for 5 min. The pellet was resuspended in 100 μl of sterile 
distilled water, frozen at -20°C for 30 min, then heated at 95°C for 3 
min. This thermolysis procedure was repeated twice in order to 
burst a large number of cells. After centifugation at 7000 rpm for 10 
min, 2 μl of the supernatant (containing the DNA) were used in the 
amplification reaction (PCR) (Rodrigues Cavalcanti et al., 2007). 
For, amplification, universal primers, fD1 
(5’AGAGTTTGATCCTGGCTCAG3’) and Rs16 (5’ 
TACGGCTACCTTGTTACGACTT 3’), used in the identification of 
bacteria by sequencing of 16S rDNA were selected (Weisberg et 
al., 1991). The reaction mix was prepared in a final reaction volume 
of 20 μl and contained: 4 μl of Taq buffer (5 x), 1,2 μl of MgCl2 (25 
mM), 4 μl of dNTPs (1 mM), 2 μl of fD1 (10 μM), 2 μl of Rs16 (10 
μM), 0.2 μl of Taq polymerase (5 U/μl), 4,6 μl of pure H2O and 2 μl 
of the DNA. The amplification conditions consisted of an initial 
denaturation at 94°C for 5 min, 35 cycles of denaturation at 94°C 
for 30 s, annealing at 55°C for 45 s and extension at 72°C for 1 min 
30 s; final extension was performed at 72°C for 10 min. The 
amplified fragment of approximately 1.5 Kb was visualized by 
electrophoresis using a 1% agarose gel. Two amplification controls 
were used, a negative control (T-) corresponds to a no template 
control, and a positive control (T+) corresponding to the 16S rDNA 
gene of B. subtilis. 
Sequencing of the PCR products was carried out as previously 
described (EL Guendouzi et al., 2011). Sequences were compared 
to those from reference strains using the National Center for 
Biotechnology Information (NCBI) database and the Basic Align-
ment Search Tool (BLAST) N program. Similarity was determined 
according to sequence homology as previously described (EL 
Guendouzi et al., 2011; Hassi et al., 2012). Other than sequencing 
of the 16S rRNA gene, the molecular identification of the isolates 
under study was complemented using conventional preliminary 
tests: macroscopic observation, Gram stain and growth at 50°C 
(Meyer et al., 2004). 
 
 
Precipitation of the active substance of the isolate by 
ammonium sulfate 
 
Ammonium sulfate is frequently used to precipitate water soluble 
proteins. It is one of the most commonly used methods for the con-
centration of the active protein substances secreted by microorga-
nisms in liquid culture (EL Guendouzi et al., 2011; Hassi et al., 
2012). The precipitation protocol used was described for the 
purification and characterization of antimicrobial peptides (Sub-
peptin JM4-A et JM4-B), produced by Bacillus subtilis JM4 (Shimei et 
al., 2005). Briefly, 100 ml of LB broth was inoculated with the 
selected strain and incubated at 37°C under agitation for 48 h. After 
incubation, it was centrifuged at 6000 rpm, at 4°C, for 5 min. The 
supernatant was recovered and 52.3 g of ammonium sulfate were 
progressively added under agitation. The mixture was left overnight 
under  agitation  at  4°C.  The  precipitate  was centrifuged at 10000  




rpm, at 10°C, for 20 min. The pellet was re-suspended in 200 μl of 
potassium phosphate buffer (KH2 PO4, 50 mM, pH = 6). The sus-
pension obtained was dialyzed against the same buffer at 4°C for 
12 h. The dialysate was filtered using a 0.45 µm de porosity filter. 
The effect of the dialysate was then tested (3 x) against M. aurum 
and M. smegmatis using the well method. 
The controls used in this experiment were the LB broth (with no 
inoculums) and the LB broth inoculated with E. coli. These controls 
were precipitated by ammonium sulfate, using same protocol for the 
precipitation of the active substance of the strain under study. The 
effect of the dialysate of these two controls was tested (three times) 
against M. aurum and M. smegmatis using the well method. The 
inhibition test was repeated three times. 
 
 
Sensitivity of the isolate’s protein precipitate to proteinase K 
 
 A 100 µl volume of the filtered dialysate was added to 40 µl of a 
proteinase K solution (1 mg/ml). The mixture was homogenized and 
incubated at 37°C for 3 h. The effect of the proteinase K treated 
dialysate, was tested (three times) against M. aurum and M. smegmatis 
using the well method (Hassi et al., 2007; EL Guendouzi et al., 
2011). The control was a solution of proteinase K at the same con-
centration. The test was repeated three times. 
 
 
Effect of the bioactive metabolite from the study isolate on the 
mycobacterial cell wall 
 
In order to determine if contact with the bioactive metabolite 
secreted by the isolate resulted in lysis of the mycobacterial cell 
wall, its effect on the extraction of genomic DNA of M. smegmatis 
was studied as follows: A 3 ml volume of an overnight culture of M. 
smegmatis was centrifuged at 5000 rpm for 5 min. The bacterial 
pellet was resuspended in 400 μl of the bioactive metabolite, pre-
pared using ammonium sulfate as described above, and recovered 
after the precipitation step in sterile distilled water instead of potas-
sium phosphate buffer. The bacterial suspension was incubated at 
37°C for 3 h and centrifuged at 5000 rpm for 5 min. The super-
natant was then treated twice with phenol-chloroform. The DNA 
was precipitated using ethanol absolute, washed with 70% ethanol 
then dried, and finally dissolved in 20 µl of Tris-EDTA (TE) buffer 
(pH = 8) for electrophoretic analysis using agarose gel (1%). This 
experiment was repeated three times. Two controls were used; the 
first corresponded to M. smegmatis treated with the protein precipi-
tate of the non-inoculated LB broth, and the second to the use of 
classical mycobacterial DNA extraction procedure (Houssaini-Iraqui 





Isolation of a bacterial strain secreting a metabolite 
with antimycobacterial effect 
 
One bacterial strain was isolated from the samples 
analyzed. It exerted a growth inhibitory effect against the 
indicator mycobacterial strains (Figure 1). 
The filtrate from the isolate exerted growth inhibition 
against the indicator mycobacterial strains as seen by the 
formation of inhibition zones (Table 1). The E. coli filtrate, 
used as control, did not present any antimycobacterial 
activity. The inhibitory effect of the active substance from 
each strain was relatively more important against M. 
aurum than M. smegmatis. 






Halo of growth inhibition 
Culture of the isolated strain 
Culture of M. smegmatis 
 
 




Table 1. Antimycobacterial effect of the filtrate from the study isolate. 
 
Filtrate 
Diameter of the inhibition zone (mm) 
Effect against MC
2
 Effect against A
+
 
Filtrate from the study isolate 23 ± 0,7 26 ± 0,5 




, M. smegmatis ; A
+




Table 2. Activity spectrum of the study isolate. 
 
Bacterial species tested 
M.  aurum 
(mycobacteria) 














+ + + + + 
 




Activity spectrum of the isolate 
 
Results of the activity spectrum of the isolate are shown 
in Table 2. These show that the isolate exerts an anti-
microbial effect for all the bacterial strains tested. 
 
 
Identification of the study isolate 
 
In order to classify a microorganism within a genus or as 
a species, a number of criteria must be respected. The 
molecular definition of genus states that 16S rRNA 
sequence similarity should be superior or equal to 97%. 
Similarity superior to 99% indicates identical species; on 
the other hand, no identification results if the similarity is 
inferior to 97%. (Drancourt et al., 2000). Results of the 
sequences obtained using primers Rs16 and fD1, 762 bp 
and 551 bp respectively, were compared to those of the 
data base. According to the identification criteria des-
cribed, results from the sequence analysis, indicated that 
the isolate corresponded to a strain of Staphylococcus 
warneri (Table 3). This result was also confirmed by the 




Determination of the protein nature of the active 
substance of isolate S. warneri 
 
Sensitivity of the active substance from S. warneri to 
proteinase K 
 
The results obtained concerning the mycobacterial 
growth inhibitory effect of the protein extract from the 
study isolate are shown in Table 4. The protein extract 
from the study isolate exerted a growth inhibitory effect 
against mycobacteria showing an inhibition zone around 
the wells. This extract was inactivated upon treatment




Table 3. Identification of the study isolate. 
 
Bacterial species showing a high degree of 
sequence similarity with the isolates under study 
% of similarity obtained using 
primer Rs16 
% of similarity obtained using 
primer fD1 
Staphylococcus warneri (strain G72) (HQ407248)
a
 100% 100% 
















Table 4. Sensitivity of the active substance from S. warneri to proteinase K. 
 
Protein precipitate 
Diameter of the inhibition zone (mm) 
Precipitate not subject to Proteinase K treatment Precipitate treated by Proteinase K 
Effect against MC
2
 Effect against A
+
 Effect against MC
2
 Effect against A
+
 
S. warneri  25 ± 1,4 28 ± 1,2 0 0 
E.  coli 0 0 - - 




, M. smegmatis; A
+




with proteinase K (Table 4). A proteinase K solution, used 
as control, showed no antimycobacterial activity. No 
inhibition zones around the wells were observed for the 




Effect of the bioactive metabolite on the mycobacterial 
cell wall 
 
The bioactive metabolite secreted by S. warneri, was 
tested for its capacity to lyse the cell wall of M. 
smegmatis. Results are shown in Figure 2. The protein 
extract from S. warneri allowed the extraction of DNA 
from M. smegmatis as efficiently as with the classic 
method. The control (non-inoculated LB broth culture pro-






The sample analyzed allowed the isolation of a bacterial 
strain of which the culture filtrate was capable of inhibiting 
mycobacterial growth due to the diffusion of an active 
substance produced on LB-agar. The inhibitory effect of 
the active substance of the study strain was relatively 
more accentuated against M. aurum than M. smegmatis. 
This difference could be due to the fact M. aurum has a 
longer generation time than M. smegmatis, which would 
allow for a more consequent diffusion of the inhibitory 
substance. Since the filtrate of this isolate was active 
against M. aurum, it is very probable that it would also be 
active against M. tuberculosis due to the fact that these 
two mycobacterial species have the same antibiotic 
susceptibility spectrum (Chung et al., 1995). 
Results from the study of the activity spectrum of the 
isolate indicated that it exerted an antimicrobial effect 
against Gram positive bacteria (B. subtilis, S. haemolyticus), 
Gram negative bacteria (E. coli) and mycobacteria (M. 
smegmatis, M. aurum). Molecular analysis identified the 
isolate as a strain of S. warneri. This study shows for the 
first time that this species secretes an active substance   
against mycobacterial growth. Other studies have shown 
that the genus Staphylococcus includes several species 
(S. haemolyticus, S. aureus) known for their production of 
antibacterial substances (Frenette et al., 1984; Beaudet 
et al., 1982; Hassi et al., 2007). Verdon et al. (2008) iso-
lated a strain of S. warneri that inhibited the growth of 
Bacillus megaterium and Legionella pneumophila. 
This study reports for the first time a strain of S. warneri 
capable of inhibiting the proliferation of mycobacteria. 
The S. warneri extract was proteic as the ammonium sul-
fate preparation used is known to precipitate proteins 
(Shimei et al., 2005). The protein extract showed a 
growth inhibitory effect against mycobacteria; this activity 
is lost in the presence of proteinase K, which corro-
borates the protein nature of the active substance from S. 
warneri. Previous investigations have shown that S. 
aureus secretes a protein (Aureocin A53) that exerts a 
bactericidal effect against lactic bacteria, Listeria 
monocytogenes (Oliveira et al., 1998a), and several other 
strains distant from S. aureus responsible for bovine   
mastitis (Oliveira et al., 1998b). Hassi et al. (2007) also 
showed that S. haemolyticus produced a protein that 
inhibited mycobacterial growth. The protein extract from 
S. warneri was capable of extracting mycobacterial DNA 













Figure 2. Extraction of genomic DNA from M. smegmatis
 
by the bioactive metabolyte
 
from S. warneri. T1, Extract using the protein precipitate from non-inoculated LB broth; 
T2, extract from M. smegmatis prepared using a conventional DNA extraction method 
(Houssaini-Iraqui et al., 1991); T3,  extract from M. smegmatis prepared using the S. 




and RNA, in the absence of conventional cell lysing 
agents (lysozyme, SDS, proteinase K). This shows that 
the active substance acts upon the cell wall of M. 
smegmatis. This result suggests that the growth inhibition 






This investigation focused on a bacterial strain isolated 
from a Moroccan biotope identified as S. warneri. This 
isolate secreted an active substance of protein nature 
that inhibited the growth of mycobacteria as well as Gram 
positive and negative bacteria. This active substance was 
capable of extracting DNA and RNA from M. smegmatis 
and therefore, may be useful in the extraction of the 
mycobacterial genome in molecular engineering. Since 
mycobacteria infect macrophages, the effect of the active 
substance may be tested ex vivo. Finally, this effect will 
also be tested against pathogenic bacteria, namely those 
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